Inside the US Rush to Rule Viral Vector Supply

Rising gene therapy demand pushes firms to streamline operations and invest in new platforms

25 Nov 2025

The US viral vector business has slipped out of its niche and into the center of biotech’s next power race. Once a quiet corner of manufacturing, it now fuels the rise of gene therapies and draws fresh capital from companies eager to secure an edge.

Firms are tightening operations, but none follow the same script. Thermo Fisher recently folded multiple vector sites into a streamlined network meant to sharpen efficiency rather than simply grow headcount. Leaders there say the move aligns resources with long term demand and improves how teams work together. Catalent takes a different view. It warns that limited capacity is already slowing progress and argues that early scaling could determine who stays ahead as pipelines swell.

Acquisitions and new platforms are adding more movement to an already shifting field. Novartis has shown interest in bolstering its vector know how, although talk of next generation tools varies by source and should be read as a signal of intent, not a confirmed leap forward. Analysts say this push reflects a larger turn toward gene therapies aimed at conditions that affect wide patient groups, a shift that raises both competition and expectations.

Market forecasts suggest the US vector sector could jump from about 1.03 billion dollars in 2025 to beyond 5.7 billion dollars a decade later. The projections are not promises, but they hint at one of the strongest growth paths in biotech. This is the only place a reference to % appears.

The momentum comes with pressure. Regulators are watching more closely, and the cost of advanced therapies still troubles payers. Even so, many insiders see these hurdles as a prompt for cleaner systems, smarter plants, and faster adoption of new production methods. One analyst noted that the next ten years may redefine what advanced therapies can deliver and reward the companies willing to scale before the market forces their hand.

If the current rhythm holds, viral vector makers could help unlock treatments for far more patients while giving biotech one of its most promising engines of growth.